Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
epifriedelinol
- Development stage
- Preclinical
- Modality
- Classical Binding Small Molecules → Small Molecules
- Administration
- Oral, Subcutaneous, Intravenous, Intramuscular, Intranasal, Inhalation, Rectal, Topical, Intraperitoneal, Intragastric
01
Overview
Epifriedelinol (EFD) is a natural triterpene compound isolated from the plant *Aster tataricus* L.fil. It is being investigated as a potential therapeutic agent for osteoporosis and other osteoclast-related bone disorders. The compound works by inhibiting osteoclast differentiation and bone resorption through the suppression of the Mitogen-Activated Protein Kinase (MAPK) signaling pathway, specifically targeting ERK, JNK, and p38. This inhibition leads to the downregulation of key transcription factors, including Nuclear factor of activated T-cells, cytoplasmic 1 (NFATc1) and Proto-oncogene c-Fos, which are essential for the expression of osteoclast-specific genes. In vitro studies have demonstrated that epifriedelinol reduces bone resorption in a dose-dependent manner without significant cytotoxicity at therapeutic concentrations.
- Other names
- 3-beta-friedelanolepifriedelanol
02
Targets
JNK (Mitogen-activated protein kinase kinase kinase family)RK (Ribokinase)MAPK3 (Mitogen-activated protein kinase 1)MEKFOS (Activator Protein 1)MAPK14 (p38 mitogen-activated protein kinase alpha)
Beyond the preview
Go deeper on epifriedelinol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on epifriedelinol.